Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

232.16

-0.61 (0.26%)

as of Jun 8, 2026, 8:00:00 pm Market Open.

698 watching

Investor Insights

Jun 8, 2026, 12:00 am

This summary was created by AI, based on 12 opinions in the last 12 months.

Johnson & Johnson (JNJ) has been experiencing a transformative period, especially following the spinoff of its orthopedics division, allowing it to focus more on pharmaceuticals and medical devices. Experts have highlighted the company's strong drug pipeline and robust performance in its core pharmaceutical business, which has led to a significant increase in stock value this year. Despite some concerns regarding ongoing talcum powder litigation and its past underwhelming performance, many analysts believe the legal risks are diminishing. The stock is seen as a better long-term hold, with potential dividend growth, especially amidst a broader economic context affecting consumer products. Overall, JNJ is viewed as an attractive investment, particularly when bought on weakness, with the valuation appearing favorable due to its premium position in the healthcare sector.

Consensus

Buy

Valuation

Fair Value

Similar

TOP PICK

Globally diversified operations including pharmaceutical, medical devices and consumer products. Over half their business is outside of the US. Trading around 8X EBITDA. Virtually no net debt. Have a real diverse group of pharmaceuticals coming on in the next 4 years. Good defensive holding.

TOP PICK

Not a purely pharmaceutical company. Also healthcare and medical devices. Great dividend and great balance sheet. Warner-Lambert was a great acquisition.

TOP PICK

High quality large-cap and is undervalued. Trading at the lowest multiple in its 20-year history. You're getting it at about 11X earnings.

BUY

Very well positioned. A defensive name so has held up very well. Consistent in their earnings streams so you don't have to be concerned about dividends. Starting to expand into growing areas i.e. medical devices as well as having a fairly large international expansion plan.

TOP PICK

Diversified businesses including consumer products, medical devices and pharmaceuticals. Great balance sheet. Created great shareholder value. 3.5% dividend.

BUY

Have a very strong consumer product business and thinks they could weather pharmacy pipeline issues. 11 PE.

BUY

Great company. 3 areas they concentrate on. Pharmaceuticals, consumer side and medical device side. The only one giving them any trouble is the pharma side where they have some generic competition. Trading at about 10X earnings. Good dividend and strong balance sheet.

HOLD

Great company and diversified between consumer products, medical devices and prescription pharmaceuticals. Until recently has been hanging in very well. Long-term you have great growth.

TOP PICK

Very strong balance sheet. Have 3 really great businesses including consumers, medical devices and pharmaceuticals. Made a very good acquisition from Pfizer (PFE-N) of their consumer products. Nice dividend of 4.5%.

HOLD

Have medical devices, consumer healthcare and pharmaceuticals. Pharma has had a lot of patent expiries in the last few years but it will start to grow in 2010. Suspects they will increase the dividend in April.

BUY

One of the most respected companies globally. Should be able to produce good growth. Bought Pfizer's (PFE-N) consumer business. Trading at the lowest multiple that they have traded at in at least 20 years.

TOP PICK

Great balance sheet. Great assets from consumers to medical devices to pharmaceuticals. In this environment, they can really grow their business through acquisition in the healthcare area. Almost 4.5% yield. Doesn't think it will fall a lot.

HOLD

More defensive than not. Has a great set of products. Longer-term it could regain its status as a defensive stock.

BUY

Great company. You get the benefit of both pharmaceutical and consumer sides. Pristine balance sheet. Good dividend. Great core holding in any portfolio.

TOP PICK

Not a pure pharmaceutical company. Has a consumer part. Made a very good acquisition of Pfizer’s (PFE-N) consumer related products. Lots of cash. Going into the cosmetic surgery business. 3% yield.

Showing 481 to 495 of 626 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)